Abstract
We investigated the effects of co-administration of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitor and angiotensin II type 1 receptor blocker (ARB) on nitric oxide (NO) bioavailability in genetically hyperlipidemic rabbits with our newly developed NO sensor. A total of 36 myocardial infarction-prone Watanabe heritable hyperlipidemic (WHHLMI) rabbits equally derived (n=6 per group) were treated with 1) vehicle (control), 2) hydralazine (15 mg/kg/d), 3) the HMG-CoA reductase inhibitor pitavastatin (P: 0.5 mg/kg/d), 4) the ARB valsartan (V: 5 mg/kg/d), and 5) pitavastatin+valsartan (P+V) together without or 6) with NG-nitro-L-arginine methyl ester (L-NAME) for 8 weeks. After treatment, acetylcholine (ACh)-induced NO production was measured as a surrogate for endothelium protective function, and vascular peroxynitrite (a product of superoxide and NO) was measured for assessing dysfunctional endothelial NO synthase activity. Plaque area was quantified by histology as well as optical coherence tomography (OCT). Intra-aortic infusion of ACh produced an increase in plasma NO concentration, which was significantly greater with all drug treatments than with the control. P+V increased ACh-induced NO by 4.1 nmol/L significantly more than either P or V singly. The vascular peroxynitrite concentration was 1.6 pmol/mg protein in the control group and significantly less than those in the P- and V-monotherapy-groups. The lowest peroxynitrite concentration was observed in the P+V group (0.4 pmol/mg protein), which was significantly lower than those in the P- and the V-monotherapy-groups. OCT and histology of the thoracic aorta revealed that the plaque area decreased significantly more with the combination than with the monotherapy. In conclusion, the combined treatment with an HMG-CoA reductase inhibitor and an ARB may have additive protective effects on endothelial function as well as atherosclerotic change.
Similar content being viewed by others
Article PDF
References
Libby P, Theroux P : Pathophysiology of coronary artery disease. Circulation 2005; 111: 3481–3488.
Kannel WB : Risk stratification in hypertension: new insights from the Framingham Study. Am J Hypertens 2000; 13: 3S–10S.
Ginsberg HN, Stalenhoef AF : The metabolic syndrome: targeting dyslipidemia to reduce coronary risk. J Cardiovasc Risk 2003; 10: 121–128.
Sowers JR : Effects of statins on the vasculature. Implications for aggressive lipid management in the cardiovascular metabolic syndrome. Am J Cardiol 2003; 91: 14B–22B.
Kjeldsen SE, Julius S : Hypertension mega-trials with cardiovascular and points: effect of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers. Am Heart J 2004; 148: 747–754.
Mochizuki S, Miyasaka T, Goto M, et al: Measurement of acetylcholine-induced endothelium-derived nitric oxide in aorta using a newly developed catheter-type nitric oxide sensor. Biochem Biophys Res Commun 2003; 306: 505–508.
Neishi Y, Mochizuki S, Miyasaka T, et al: Evaluation of bioavailability of nitric oxide in coronary circulation by direct measurement of plasma nitric oxide concentration. Proc Natl Acad Sci U S A 2005; 102: 11456–11461.
Imanishi T, Kobayashi K, Kuroi A, et al: Effects of angiotensin II on NO bioavailability evaluated using a catheter-type NO sensor. Hypertension 2006; 48: 1058–1065.
Nickenig G : Should angiotensin II receptor blockers and statins be continued? Circulation 2004; 110: 1013–1020.
Suzuki H, Yamazaki H, Aoki T, et al: Lipid-lowering and antiatherosclerotic effect of NK-104, a potent 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor, in Watanabe heritable hyperlipidemic rabbits. Arzneimittelforschung 2000; 50: 995–1003.
Ter Steege JCA, Koster-Kamphuis L, Van Straaten EA, et al: Nitrotyrosine in plasma of celiac disease patients as detected by a new sandwich ELISA. Free Radic Biol Med 1998; 25: 953–963.
Jang IK, Tearney GJ, MacNeill B, et al: In vivo characterization of coronary atherosclerotic plaque by use of optical coherence tomography. Circulation 2005; 111: 1551–1555.
Imanishi T, McBride J, Ho Q, O’Brien KD, Schwartz SM, Han DK : Expression of cellular FLICE-inhibitory protein in human coronary arteries and in a rat vascular injury model. Am J Pathol 2000; 156: 125–137.
Balk EM, Karas RH, Jordan HS, Kupelnick B, Chew P, Lau J : Effects of statins on vascular structure and function; a systemic review. Am J Med 2004; 117: 775–790.
O’Driscoll G, Green D, Rankin J, Stanton K, Taylor R : Improvement in endothelial function by angiotensin converting enzyme inhibition in insulin-dependent diabetes mellitus. J Clin Invest 1997; 100: 678–684.
Cheetham C, Collis J, O’Driscoll G, Stanton K, Taylor R, Green D : Losartan, an angiotensin type 1 receptor antagonist, improves endothelial function in non-insulin-dependent diabetes. J Am Coll Cardiol 2000; 36: 1461–1466.
Hornig B, Lnadmesser U, Kohler C, et al: Comparative effect of ACE inhibition and angiotensin II type 1 receptor antagonist on bioavailability of nitric oxide in patients with coronary artery disease: role of superoxide dismutase. Circulation 2001; 103: 799–805.
Tao L, Liu HR, Gao E, et al: Antioxidative, antinitrative, and vasculoprotective effects of a peroxisome proliferator-activated receptor-γ agonist in hypercholesterolemia. Circulation 2003; 108: 2805–2811.
Griendling KK, Minieri CA, Ollerenshaw JD, Alexander RW : Angiotensin II stimulates NADH and NADPH oxidase activity in cultured vascular smooth muscle cells. Circ Res 1994; 74: 1141–1148.
Rajagopalan S, Kurz S, Munzel T, et al: Angiotensin II-mediated hypertension in the rat increases vascular superoxide production via membrane NADH/NADPH oxidase activation. J Clin Invest 1996; 97: 1916–1923.
Pagano PJ, Clark JK, Cifuentes-Pagano ME, Clark SM, Callis GM, Quinn MT : Localization of a constitutively active, phagocyte-like NADPH oxidase in rabbit aortic adventitia: enhancement by angiotensin II. Proc Natl Acad Sci U S A 1997; 94: 14483–14488.
Warnholtz A, Nickenig G, Schulz E, et al: Increased NADH-oxidase-mediated superoxide production in the early stages of atherosclerosis: evidence for involvement of the renin-angiotensin system. Circulation 1999; 99: 2027–2033.
Griendling KK, FitzGerald GA : Oxidative stress and cardiovascular injury: Part I: basic mechanism and in vivo monitoring of ROS. Circulation 2003; 108: 1912–1916.
Landmesser U, Dikalov S, Price SR, et al: Oxidation of tetrahydropterin leads to uncoupling of endothelial cell nitric oxide synthesis in hypertension. J Clin Invest 2003; 111: 1201–1209.
Laursen JB, Somers M, Kurz S, et al: Endothelial regulation of vasomotion in apoE-deficient mice: implications for interactions between peroxynitrite and tetrahydrobiopterin. Circulation 2001; 103: 1282–1288.
Stuehr D, Pou S, Rosen GM : Oxygen reduction by nitric oxide synthases. J Biol Chem 2001; 276: 145333–145336.
Kawashima S, Yokoyama M : Dysfunction of endothelial nitric oxide synthase and atherosclerosis. Arterioscler Thromb Vasc Biol 2004; 24: 998–1005.
Ozaki M, Kawashima S, Yamashita T, et al: Overexpression of endothelial nitric oxide synthase accelerates atherosclerotic lesion formation in apo E-deficient mice. J Clin Invest 2002; 110: 331–340.
Horiuchi M, Cui TX, Li Z, Li JM, Nakagami H, Iwai M : Fluvastatin enhances the inhibitory effects of a selective angiotensin II type 1 receptor blocker, valsartan, on vascular neointimal formation. Circulation 2003; 107: 106–112.
Li Z, Iwai M, Wu L, et al: Fluvastatin enhances the inhibitory effects of a selective AT1 receptor blocker, valsartan, on atherosclerosis. Hypertension 2004; 44: 758–763.
Jang IK, Bouma BE, Kang DH, et al: Visualization of coronary atherosclerotic plaques in patients using optical coherence tomography: comparison with intravascular ultrasound. J Am Coll Cardiol 2002; 39: 604–609.
Yabushita H, Bouma BE, Houser SL, et al: Characterization of human atherosclerosis by optical coherence tomography. Circulation 2002; 106: 1640–1645.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Imanishi, T., Ikejima, H., Tsujioka, A. et al. Combined Effects of an 3-Hydroxy-3-Methylglutaryl Coenzyme A Reductase Inhibitor and Angiotensin II Receptor Antagonist on Nitric Oxide Bioavailability and Atherosclerotic Change in Myocardial Infarction-Prone Watanabe Heritable Hyperlipidemic Rabbits. Hypertens Res 31, 1199–1208 (2008). https://doi.org/10.1291/hypres.31.1199
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1291/hypres.31.1199
Keywords
This article is cited by
-
Neprilysin Inhibitor–Angiotensin II Receptor Blocker Combination Therapy (Sacubitril/valsartan) Suppresses Atherosclerotic Plaque Formation and Inhibits Inflammation in Apolipoprotein E- Deficient Mice
Scientific Reports (2019)
-
Baccaurea angulata fruit inhibits lipid peroxidation and induces the increase in antioxidant enzyme activities
European Journal of Nutrition (2016)
-
Plasma thrombin-cleaved osteopontin elevation after carotid artery stenting in symptomatic ischemic stroke patients
Hypertension Research (2012)